In addition, for other adverse events, the rates of nasopharyngitis, headache, gastroenteritis, upper respiratory tract infections and injection-site reactions were greater but not significantly with than without PCSK9 antibodies. The gene discussed is PCSK9; the disease is nasopharyngitis.